NBSE vs. ATNF, INM, HSTO, PBLA, GRI, PRFX, GLMD, BPTH, LSDI, and CMRA
Should you be buying NeuBase Therapeutics stock or one of its competitors? The main competitors of NeuBase Therapeutics include 180 Life Sciences (ATNF), InMed Pharmaceuticals (INM), Histogen (HSTO), Panbela Therapeutics (PBLA), GRI Bio (GRI), PainReform (PRFX), Galmed Pharmaceuticals (GLMD), Bio-Path (BPTH), Lucy Scientific Discovery (LSDI), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical preparations" industry.
180 Life Sciences (NASDAQ:ATNF) and NeuBase Therapeutics (NASDAQ:NBSE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
NeuBase Therapeutics received 47 more outperform votes than 180 Life Sciences when rated by MarketBeat users. However, 66.67% of users gave 180 Life Sciences an outperform vote while only 60.49% of users gave NeuBase Therapeutics an outperform vote.
180 Life Sciences has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, NeuBase Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 12.4% of NeuBase Therapeutics shares are owned by institutional investors. 4.1% of 180 Life Sciences shares are owned by company insiders. Comparatively, 13.9% of NeuBase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
180 Life Sciences' return on equity of -99.74% beat NeuBase Therapeutics' return on equity.
In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. NeuBase Therapeutics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score.
Summary
NeuBase Therapeutics beats 180 Life Sciences on 7 of the 8 factors compared between the two stocks.
Get NeuBase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuBase Therapeutics Competitors List
Related Companies and Tools
